https://eureka.patsnap.com/resources/blog/rd-blog/oligonucleotide-manufacturing-process-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Oligonucleotide Manufacturing
Oligonucleotide manufacturing process patents: where synthesis claims concentrate and where they don't
  • 27.3% of all 8,130 records sit with just five assignees, yet the ranked list runs 100 companies deep with a long tail of single- and few-filing entrants below tenth place.
  • Filing fell 32% from 2021 (210) to 2024 (143), the last year the dataset treats as complete once the ~18-month publication lag is accounted for.
  • C12N and C07H each cover roughly half of records, while C12P (fermentation and enzymatic synthesis) sits at just 10.1%, a much thinner claim layer than the chemistry classes above it.
Get a prior-art report on your approach
8,130
Published Records
27%
Top-5 Share of All Records
-32%
Filing Growth 2021→2024
US
Leading Jurisdiction

Filing growth compares 2021 (210 records) with 2024 (143) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 8,130 records in scope (CR5), not by the ranked leaders only.

Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview

What this landscape covers

This dataset tracks patent families addressing oligonucleotide synthesis and adjacent process controls: phosphoramidite chemistry, solid-support synthesis, coupling efficiency, detritylation control, acetonitrile consumption, column scale and deprotection conditions. It spans records published between 2015 and mid-2026, a window that captures the shift from small-scale therapeutic oligonucleotide synthesis toward the process-engineering concerns that matter at manufacturing scale. Records are drawn from filings at the United States, EPO, WIPO/PCT, Australia, Canada and AT receiving offices.

Because a single family can carry several IPC classes, and because assignees continuation-file at different rates across jurisdictions, family-level counts give a fairer read of where claim density actually sits than raw document totals do. The picture below uses that lens throughout.

Filing activity and technology composition, 2015-2026
  1. 1SIRNA THERAPEUTICS INC886
  2. 2CORIXA CORP479
  3. 3IONIS PHARMACEUTICALS INC404
  4. 4NANOSPHERE INC238
  5. 5WAVE LIFE SCI LTD209
  6. 6AFFYMETRIX INC179
  7. 7MACROGENICS INC154
  8. 8MCSWIGGEN JAMES139
  9. 9SUZHOU RIBO LIFE SCIENCE CO LTD131
  10. 10ATYR PHARM INC124
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Oligonucleotide Manufacturing Process covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Let an AI agent run this analysis on your own technology

Pick a task. Every answer cites the patents behind it.

10,000 free credits to start
The data

Filing trend and technology composition

Two views of the same 8,130 records: how filing activity has moved year over year, and which IPC subclasses carry the claim weight.

Filing trend, 2017-2026

Filings rose to a peak of 247 in 2018, then eased; the 2021-to-2024 span shows a 32% decline (210 to 143), the last three-year comparison the dataset supports before the publication lag makes 2025 and 2026 numbers provisional. Treat the 2026 figure of 22 as a floor, not a signal that filing has stopped.

Filing trend, 2017-2026063125188250148201724720182019202020212022202320242025222026Most recent year is partial — publication lag means later filings are not yet visible.

IPC subclass composition

C12N (49.2%) and C07H (45.2%) dominate, consistent with a field still centred on the genetic-engineering and nucleic-acid chemistry itself. A61K (44.5%) and C12Q (25.0%) show the therapeutic-formulation and testing layers are well populated too, while C12P at 10.1% marks fermentation and enzymatic synthesis routes as comparatively open.

IPC subclass compositionC12N · Microorganisms & genetic engin…3,99949.2%C07H · Sugars & nucleic acids3,67445.2%A61K · Medicinal preparations3,61444.5%C07K · Peptides & proteins2,23427.5%C12Q · Measuring & testing involving …2,03025.0%A61P · Therapeutic activity of compou…1,52618.8%G01N · Material analysis & testing1,51818.7%C12P · Fermentation & enzymatic synth…82110.1%Other5,22364.2%

Shares are the percentage of the 8,130 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Oligonucleotide Manufacturing Process covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Oligonucleotide Manufacturing Process with Eureka

This page is one run against one query. Ask Eureka your own question about oligonucleotide manufacturing process and every answer comes back with the patent numbers behind it.

Try Eureka
Key patents

The records other filings cite most

Representative record
US20090317873A12009-12-24

US20090317873A1 — Design, synthesis and assembly of synthetic nucleic acids

DNA TWOPOINTO, INC.

Methods of synthesizing oligonucleotides with high coupling efficiency (>99.5%) are provided, alongside purification methods, instrumentation configurations, and design/assembly methods optimised for building longer polynucleotides from shorter oligonucleotide segments, including codon-bias-aware design for host expression.Filed by DNA Twopointo, Inc.; published 2009-12-24.

US20090317873A1 — patent drawing 1US20090317873A1 — patent drawing 2
View full record
Most-cited records in scope
#Publication no.Patent titleCitations
1US5034506AUncharged morpholino-based polymers having achiral intersubunit linkages6,574
2US5744305AArrays of materials attached to a substrate4,474
3US5185444AUncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages3,804
4US5519134APyrrolidine-containing monomers and oligomers3,307
5US5608046AConjugated 4'-desmethyl nucleoside analog compounds3,064
6US5525711APteridine nucleotide analogs as fluorescent DNA probes2,947
7US5585481ALinking reagents for nucleotide probes2,857
8US5681941ASubstituted purines and oligonucleotide cross-linking2,747
9US5367066AOligonucleotides with selectably cleavable and/or abasic sites2,704
10US5596091AAntisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides2,648

Citation counts accumulate over time, so older morpholino- and array-chemistry patents dominate this list; that reflects influence within the searched corpus, not which claims matter for a filing decision today.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Oligonucleotide Manufacturing Process covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the numbers mean for a filing decision

Three figures from this dataset carry direct implications for where new claims are likely to clear and where they are likely to collide with existing art.

Concentration
27.3% of 8,130
held by the top five assignees

The top of the field is dense, not closed

Five assignees hold just over a quarter of all records in scope, and the top ten combined reach 36.2%. That still leaves nearly two-thirds of the field spread across a ranked list of 100 companies with a pronounced long tail — concentration at the top does not mean the rest of the space is empty.

Based on the full 100-company assignee ranking
Momentum
-32% (2021→2024)
three-year filing change

Filing has cooled from its post-2018 pace

The peak year was 2018 at 247 filings; by 2024, the last year the dataset treats as complete, annual filings had fallen to 143 from 210 in 2021. Read 2025 and 2026 figures as provisional given the roughly 18-month gap between filing and publication.

2024 is the most recent complete year in this dataset
Composition
10.1% in C12P
fermentation & enzymatic synthesis

Chemical synthesis routes dominate over biological ones

C12N and C07H each touch roughly half the record set, reflecting the field's centre of gravity in solid-phase chemical synthesis and nucleic-acid chemistry. C12P, covering fermentation and enzymatic synthesis approaches to oligonucleotide production, sits far lower at 10.1%, marking it as the thinner-claimed alternative route.

Shares exceed 100% because records carry multiple IPC classes
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to oligonucleotide manufacturing process, with the prior art for and against each one.

Find the white space →
Co-assignee activity
AssigneeCo-assigneeShared families
Sirna Therapeutics, Inc.MCSWIGGEN JAMES127
MCSWIGGEN JAMESBEIGELMAN LEONID106
Sirna Therapeutics, Inc.BEIGELMAN LEONID74
MCSWIGGEN JAMESUSMAN NASSIM40
Wave Life Sciences LtdVARGEESE CHANDRA38
Sirna Therapeutics, Inc.VARGEESE CHANDRA35
Corixa CorpWANG TONGTONG29
Corixa CorpHARLOCKER SUSAN L29

Co-filing is limited and concentrated: of 10 identified co-assignee pairs, the strongest links run through a small cluster of individual inventors and their affiliated corporate assignees, rather than broad industry consortia.

Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Oligonucleotide Manufacturing Process covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players

Who is filing, and where the gate sits

The assignee ranking runs 100 companies deep, but a small group at the top account for over a third of all records. Recent-year momentum, however, shows even leading assignees pulling back or going quiet.

Leader
886 records
single largest assignee

One assignee sits well ahead of the field

The leading assignee's 886 records are more than four times the fifth-place total of 209, and roughly seven times tenth place at 124. That gap suggests a portfolio built over many years of continuation filing rather than one recent surge.

Counted at the family level across the ranking
Momentum
-63% YoY
steepest recent decline among tracked assignees

Even active filers are slowing down

Among assignees with visible recent-year activity, filings are falling rather than accelerating: one tracked filer dropped 63% year over year to 9 filings, while several historically significant assignees show zero filings in the latest year.

Recent-year momentum by assignee
Long tail
100 ranked companies
full assignee ranking

The field is broader than the leaders suggest

Below the top ten, the ranked list continues for 100 companies total, with combined share falling well short of half the field even at ten deep (36.2%). New entrants are not filing into empty space, but they are not filing into a duopoly either.

This is the full ranking returned, not a top-50 or top-100 cut
🔍
Under-claimed sub-areas worth checking before drafting
These branches show thinner claim density relative to the core synthesis and formulation classes.
enzymatic/fermentation-based oligo synthesis routesacetonitrile-reduction process controlscolumn-scale process mass intensity optimisationdetritylation kinetics monitoring methodssolid-support recycling and reuse schemes
Rank all filers by momentum →
Recent-year filing momentum by assignee
AssigneeRecent yearYoY
Wave Life Sciences Ltd9-63%
Twist Bioscience Corp20%
Sirna Therapeutics, Inc.0—
Corixa Corp0—
Ionis Pharmaceuticals, Inc.0—
Nanosphere, Inc.0—
MCSWIGGEN JAMES0—
Affymetrix, Inc.0—
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Oligonucleotide Manufacturing Process covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's next

Where to take this

The dataset points to specific next steps depending on whether you are drafting, licensing, or scouting for freedom to operate.

Check freedom to operate against the leader's portfolio

With one assignee holding 886 records against a fifth-place total of 209, any new coupling-efficiency or detritylation claim should be checked against that portfolio's continuation chain before drafting.

Run a freedom-to-operate scan in Eureka

Draft into the enzymatic-synthesis gap

C12P's 10.1% share against C12N's 49.2% and C07H's 45.2% suggests fermentation and enzymatic routes carry materially less claim density than chemical synthesis paths.

Map white space in Eureka

Watch the assignees that just went quiet

Several historically significant filers show zero filings in the latest year, which can mean a licensing opportunity or a strategic pivot worth confirming directly.

Track assignee activity in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Oligonucleotide Manufacturing Process covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions on this landscape

Answers are grounded in the same dataset. Derived from a Patsnap search on Oligonucleotide Manufacturing Process covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Oligonucleotide Manufacturing Process in depth with Eureka

Go past this page: query the whole oligonucleotide manufacturing process corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.